Navigation Links
Apexigen, Inc. Announces Collaboration for Antibody Discovery

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.  Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.  While financial details were not disclosed, Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialization milestones are achieved.

Apexigen's antibody technologies produce a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail. This enables the development of 'best-in-class' therapeutic antibodies.  

"We're excited about this collaboration and look forward to working closely with Centocor R&D," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "Our goal is to become a world leader in the development of best-in-class therapeutic antibodies.  To achieve this goal, we plan to collaborate with partners while also developing our own product pipeline."

About Apexigen

Apexigen, Inc. is a biopharmaceutical company focused on the discovery and development of best-in-class therapeutic antibodies.  Apexigen has exclusive rights to the proprietary antibody technologies that were developed by Epitomics, Inc. for the development and commercialization of human therapeutics. In addition, Apexigen assumed development and commercialization responsibility for a pipeline of therapeutic product programs initiated by Epitomics.

Located in Burlingame, CA, Apexigen is actively developing its internal therapeutic product pipeline and seeking to form collaborative relationships with pharmaceutical and biotechnology companies for the discovery and development of pharmaceutical products based on its humanized rabbit monoclonal antibody technologies.  More information about Apexigen is available at Mark Nevins, Vice President, Business DevelopmentTel: 650-931-6236, ext. 502Email:

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
2. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
3. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
4. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
5. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
6. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
9. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
10. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
11. Curemark Announces Four New Sites Participating in Autism Study
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):